AHDA Fights Back Against Barriers to Migraine and Headache Care
For people living with migraine and other headache disorders, access to the right treatment at the right time can be life-changing. But too often, patients face unnecessary barriers before they can receive the care their clinician believes is medically appropriate.
At the Alliance for Headache Disorders Advocacy, part of our work is watching for policy changes that could make those barriers worse, and speaking up before they take effect.
That is why AHDA recently submitted comments to Medicare Administrative Contractors, also known as MACs, regarding proposed Local Coverage Determinations for botulinum toxin injections, including onabotulinumtoxinA, commonly known as Botox, for chronic migraine.
A Local Coverage Determination, or LCD, is a policy issued by a regional Medicare contractor that determines whether and under what circumstances Medicare will cover a particular service. These policies may sound technical, but they can have a very real impact on whether patients can access treatment.
In this case, AHDA is concerned that the proposed LCDs could make it harder for Medicare beneficiaries with chronic migraine to continue receiving botulinum toxin treatment, even when they are benefiting from it.
The proposed policy would require patients to meet strict documentation and response criteria, including a 50 percent reduction in migraine days and episodes, along with improvement in disability and functioning, to support continued therapy. The proposed LCD also includes requirements related to concurrent CGRP therapy, behavioral therapy documentation, standardized functional measures, and treatment intervals.
AHDA urged the MACs to revise these criteria so that coverage decisions better reflect real-world clinical care. Migraine improvement is not always captured by a single number. A patient may still experience meaningful benefit through reduced severity, shorter attacks, improved response to acute medication, fewer emergency visits, or improved ability to work, care for family, attend school, or participate in daily life.
A rigid 50 percent threshold could force some patients off an effective treatment simply because their improvement does not fit neatly into a coverage policy.
AHDA also raised concerns that the proposed policy could add to the already heavy administrative burden facing clinicians who treat headache disorders. There are far too few headache specialists in the United States to meet patient need, and many patients rely on general neurologists or other clinicians for care. When coverage policies become overly complex, patients can lose access not because a treatment is inappropriate, but because documentation requirements are too burdensome or too disconnected from clinical practice.
The issue is part of a larger concern: while federal policymakers have increasingly recognized the need to reduce prior authorization and other utilization management burdens, policies like these could move in the opposite direction for people with migraine and headache disorders.
AHDA’s comments emphasized that Medicare coverage policies should support timely, individualized, evidence-informed care. We urged the MACs to:
-Allow continued coverage based on clinically meaningful improvement, not only a strict 50 percent reduction in migraine days or episodes;
-Recognize improvements in severity, duration, acute medication use, disability, and daily functioning;
-Avoid step therapy requirements that delay access to appropriate treatment;
-Allow flexibility for patients using both botulinum toxin and CGRP-targeting therapies when clinically appropriate;
-Ensure behavioral therapy documentation does not become a barrier to pharmacologic treatment;
-Permit clinician attestation and patient-reported outcomes as valid ways to document functional improvement; and
-Recognize that chronic migraine is a fluctuating neurologic disease, and that patients may still need treatment even when they have improved but remain disabled.
AHDA is not opposed to thoughtful coverage policy. Medicare must have standards to ensure appropriate use of covered services. But those standards should be grounded in clinical reality, reflect current treatment options, and avoid creating unnecessary barriers for patients who already struggle to access specialized headache care.
These letters are one example of how AHDA works behind the scenes to protect access to care. We monitor federal policy, Medicare coverage decisions, proposed rules, legislative developments, and regulatory changes that may affect people living with migraine, cluster headache, facial pain, and other headache disorders.
When a policy could harm patients, increase delays, or make it harder for clinicians to provide appropriate care, AHDA speaks up.
Access to migraine and headache disorder treatment should not depend on whether a patient can navigate an overly rigid system. People living with these diseases deserve coverage policies that recognize the complexity of their condition, the expertise of their clinicians, and the real-world improvements that can change a person’s life.
AHDA will continue fighting for policies that reduce barriers, protect access, and move us closer to a health care system that takes migraine and headache disorders seriously.